סרוקואל 400 מג xr
astrazeneca (israel) ltd - quetiapine fumarate - טבליות עם שחרור נרחב - quetiapine fumarate 400 mg - quetiapine
קוסליוגו 10 מג
astrazeneca (israel) ltd - selumetinib as hyd-sulfate - קפסולה קשיחה - selumetinib as hyd-sulfate 10 mg - selumetinib
קוסליוגו 25 מג
astrazeneca (israel) ltd - selumetinib as hyd-sulfate - קפסולה קשיחה - selumetinib as hyd-sulfate 25 mg - selumetinib
קסיגדו 10 מג 1000 מג xr
astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 1005.04 mg; dapagliflozin propanediol 12.30 mg - metformin and dapagliflozin
קסיגדו 10 מג 500 מג xr
astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 502.61 mg; dapagliflozin propanediol 12.30 mg - metformin and dapagliflozin
קסיגדו 5 מג 1000 מג xr
astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 1005.04 mg; dapagliflozin propanediol 6.150 mg - metformin and dapagliflozin
קסיגדו 5 מג 500 מג xr
astrazeneca (israel) ltd - dapagliflozin propanediol; metformin hydrochloride - טבליות עם שחרור נרחב - metformin hydrochloride 502.61 mg; dapagliflozin propanediol 6.150 mg - metformin and dapagliflozin
נקסיום טבליות 20 מג
astrazeneca (israel) ltd - esomeprazole - טבליה - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.
נקסיום טבליות 40 מג
astrazeneca (israel) ltd - esomeprazole - טבליה - esomeprazole 40 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.
אונגלייזה 5 מג
astrazeneca (israel) ltd - saxagliptin as hydrochloride - טבליות מצופות פילם - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.